Efficacy of a Persian herbal medicine compound on coronavirus disease 2019 (COVID-19): a randomized clinical trial
Small RCT 41 patients treated with nigella sativa, glycyrrhiza glabra, punica granatum, and rheum palmatum, and 41 control patients, showing shorter hospitalization with treatment.
risk of death, 7.9% higher, RR 1.08, p = 1.00, treatment 1 of 38 (2.6%), control 1 of 41 (2.4%).
oxygen time, 26.8% lower, relative time 0.73, p = 0.007, treatment mean 3.0 (±1.6) n=38, control mean 4.1 (±1.9) n=41.
hospitalization time, 28.7% lower, relative time 0.71, p < 0.001, treatment mean 5.7 (±1.9) n=38, control mean 8.0 (±1.8) n=41.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Setayesh et al., 3 Jun 2022, Randomized Controlled Trial, Iran, peer-reviewed, mean age 59.1, 7 authors, study period June 2020 - September 2020, this trial uses multiple treatments in the treatment arm (combined with glycyrrhiza glabra, punica granatum, and rheum palmatum) - results of individual treatments may vary, trial IRCT20200330046899N1
Abstract: Integrative Medicine Research 11 (2022) 100869
Contents lists available at ScienceDirect
Integrative Medicine Research
journal homepage: www.elsevier.com/locate/imr
Eﬃcacy of a Persian herbal medicine compound on coronavirus
disease 2019 (COVID-19): A randomized clinical trial
Mohammad Setayesh a, Mehrdad Karimi b, Arman Zargaran c, Hamid Abousaidi d,
Armita Shahesmaeili e, Fatemeh Amiri f, Fatemeh Sadat Hasheminasab g,∗
Department of Traditional Medicine, School of Persian medicine, Kerman University of Medical Sciences, Kerman, Iran
Department of Traditional Medicine, School of Persian Medicine, Tehran University of Medical Sciences, Tehran, Iran
Department of Traditional Pharmacy, School of Persian Medicine, Tehran University of Medical Sciences, Tehran, Iran
Research Center of Tropical and Infectious Diseases, Kerman University of Medical Sciences, Kerman, Iran
HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health Kerman University of
Medical Sciences, Kerman, Iran
Afzalipour Hospital, Kerman University of Medical Sciences, Kerman, Iran
Pharmacology Research Center, Zahedan University of Medical Sciences, Zahedan, Iran
a r t i c l e
i n f o
Received 31 December 2021
Revised 27 May 2022
Accepted 30 May 2022
Available online 3 June 2022
a b s t r a c t
Background: The global attention to the capacities of traditional medicine for alleviating the clinical manifestations of COVID-19 has been growing. The present trial aimed to evaluate the eﬃcacy and safety of
a Persian herbal medicine formula among patients with COVID-19.
Methods: The present trial was conducted in Afzalipour hospital, Kerman, Iran, from June to September
2020. Hospitalized COVID-19 patients were randomly divided into intervention (Persian herbal medicine
formula + routine treatment) or control (only routine treatment) groups. The intervention group received
both capsule number 1 and 2 every 8 hours for 7 days. Capsule number 1 contained extract of the Glycyrrhiza glabra, Punica granatum, and Rheum palmatum, and the second capsule was ﬁlled by Nigella sativa
powder. Participants were followed up to 7 days. The primary outcome was the number of hospitalization days, while cough, fever, and respiratory rate, days on oxygen (O2 ) therapy, and mortality rate were
considered as the secondary outcomes.
Results: Eighty-two patients were enrolled to the study, while 79 cases completed the trial and their
data were analyzed (mean age: 59.1 ± 17.1 years). Based on the results, the Persian medicine formula
decreased the mean hospitalization days, so that the mean difference of length of hospitalization as primary outcome was 2.95 ± 0.43 days. A signiﬁcant clinical improvement was observed regarding dyspnea,
need for O2 ) therapy, and respiratory rate in the intervention group. No adverse effects were reported.
Conclusion: The present study supported the use of the Persian medicine formula as an adjuvant therapy
for hospitalized COVID-19 patients. Study registration: Iranian Registry of Clinical Trials (www.irct.ir):
IRCT2020 0330 046899N1.
Study registration: Iranian Registry of Clinical Trials (www.irct.ir): IRCT2020 0330 046899N1.
© 2022 Korea Institute of Oriental Medicine. Published by Elsevier B.V.
This is an open access article under the CC..
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.